Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Share-based Compensation: 2020-2025

Historic Share-based Compensation for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Sep 2025 value amounting to $12.2 million.

  • Tarsus Pharmaceuticals' Share-based Compensation rose 65.11% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.8 million, marking a year-over-year increase of 34.41%. This contributed to the annual value of $27.8 million for FY2024, which is 40.28% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Share-based Compensation stood at $12.2 million, which was up 48.71% from $8.2 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Share-based Compensation's 5-year high stood at $12.2 million during Q3 2025, with a 5-year trough of $782,000 in Q3 2021.
  • In the last 3 years, Tarsus Pharmaceuticals' Share-based Compensation had a median value of $6.9 million in 2025 and averaged $6.8 million.
  • The largest annual percentage gain for Tarsus Pharmaceuticals' Share-based Compensation in the last 5 years was 137,250.00% (2021), contrasted with its biggest fall of 73.38% (2021).
  • Tarsus Pharmaceuticals' Share-based Compensation (Quarterly) stood at $2.2 million in 2021, then skyrocketed by 68.47% to $3.7 million in 2022, then soared by 49.33% to $5.5 million in 2023, then soared by 35.04% to $7.4 million in 2024, then spiked by 65.11% to $12.2 million in 2025.
  • Its Share-based Compensation was $12.2 million in Q3 2025, compared to $8.2 million in Q2 2025 and $6.9 million in Q1 2025.